Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors

Nutrition

Volumn 17, Issue 5, 2001, Pages 414-415

  de Luis, Daniel A ^b   Bachiller, P ^a,b   Aller, R ^a,b  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BEZAFIBRATE; CD4 ANTIGEN; CHOLESTEROL; CIS 9 RETINOIC ACID; CYTOCHROME P450 3A4; FENOFIBRATE; FLUINDOSTATIN; GLUCOSE; INDINAVIR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; PROTEINASE; PROTEINASE INHIBITOR; RETINOIC ACID DERIVATIVE; RITONAVIR; RNA; STATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVE SITE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; CHOLESTEROL; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; MALE; PROCETOFEN; TREATMENT OUTCOME; TRIGLYCERIDES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035018114     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(01)00582-2     Document Type: Article

References (10)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MD, Fuhrer J, Satten GA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51.
3. De Luis DA, Aller R, Bachiller P, Tortosa JI. Reversibilidad de hiperlipemia intensa secundaria a indinavir con fenofibrato micronizado. Med Clin (Bare) 1999;113:716.
4. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inihbitor-assciated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881.
5. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 2000;164:R7.
6. Weil A, Caldwell J, Strolin M, Dostert P. Species differences in the metabolism disposition of fenofibrate. In: De. R Paoletti et al., Drugs Affecting Lipid Metabolism, Berlin-Heidelberg: Springer Verlag, 1987:324.
7. 14C-fenofibrate in human volunteers. Drug and Metabolism and Disposition 1990; 18:115.
8. Kloer HU. Structure and biochemical effects of fenofibrate. Am J Med 1987;83:3.
9. Henry K, Melroe H, Huebesch J, Herdmundson J, Simpsom J. Atorvastatin and gemfibrozil for protease inhibitor related lipid abnormalities. Lancet 1998;352:1031.
10. Hadigan C, Meigs JB, Corcoran C, Riestschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D’Agostino PB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy. Clin Infect Dis 2001;32:130